Delcath Systems’ (DCTH) “Buy” Rating Reiterated at HC Wainwright

Delcath Systems (NASDAQ:DCTH)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They currently have a $22.00 price objective on the stock. HC Wainwright’s price objective would suggest a potential upside of 72.01% from the company’s current price.

A number of other analysts also recently weighed in on DCTH. Canaccord Genuity Group restated a “buy” rating and issued a $21.00 target price on shares of Delcath Systems in a research report on Friday, October 18th. StockNews.com raised shares of Delcath Systems from a “sell” rating to a “hold” rating in a research note on Friday, October 25th. Finally, Stephens reiterated a “buy” rating on shares of Delcath Systems in a report on Friday, October 18th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $21.50.

Delcath Systems Stock Performance

Delcath Systems stock opened at $12.79 on Tuesday. The stock has a market cap of $408.95 million, a P/E ratio of -9.47 and a beta of 0.87. Delcath Systems has a fifty-two week low of $3.70 and a fifty-two week high of $13.30. The firm’s fifty day moving average price is $11.29 and its 200-day moving average price is $9.80.

Hedge Funds Weigh In On Delcath Systems

Hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC raised its stake in Delcath Systems by 3.0% in the third quarter. Geode Capital Management LLC now owns 251,895 shares of the company’s stock worth $2,275,000 after buying an additional 7,298 shares in the last quarter. Polar Asset Management Partners Inc. purchased a new stake in Delcath Systems in the third quarter worth $1,594,000. Shellback Capital LP bought a new position in Delcath Systems in the second quarter worth $1,353,000. Marshall Wace LLP raised its holdings in Delcath Systems by 7.0% in the second quarter. Marshall Wace LLP now owns 92,731 shares of the company’s stock worth $776,000 after purchasing an additional 6,066 shares in the last quarter. Finally, Principal Financial Group Inc. purchased a new position in Delcath Systems during the third quarter valued at $808,000. 61.12% of the stock is owned by hedge funds and other institutional investors.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.